See the following -

ACRO Establishing CRO Forum To Interact With TransCelerate BioPharma Inc.

Press Release | Association of Clinical Research Organizations | October 27, 2014

The Association of Clinical Research Organizations today announced plans to constitute a CRO Forum in order to provide a formal mechanism for the CRO industry to furnish input into the work of TransCelerate BioPharma Inc. The CRO Forum, expected to commence operation in January 2015, is open to all CROs and participation is included as a benefit of ACRO membership...

Read More »

CDISC and TransCelerate Announce New Standard for Breast Cancer to Support Data Sharing for Oncology Research

Press Release | CDISC, TransCelerate BioPharma, Inc. | May 18, 2016

The need to rapidly and efficiently share new data in cancer research was recently, and powerfully, highlighted by U.S. Vice President Joe Biden as part of the Cancer Moonshot initiative. The Clinical Data Interchange Standards Consortium (CDISC) and TransCelerate BioPharma, Inc. (“TransCelerate”) announce today the open availability of a new CDISC Therapeutic Area (TA) Standard for Breast Cancer. The CDISC global TA standards can streamline the way clinical research is conducted so that data can be readily shared among clinicians, researchers and regulators around the world, thus leading to more rapid and “smarter” research...

Read More »

Medidata And TransCelerate BioPharma Inc. Announce Joint Initiative

Press Release | Medidata, TransCelerate BioPharma Inc. | May 20, 2014

Collaboration to Explore Key Components of Recommended Risk-Based Monitoring Methodology

Read More »

Re-thinking Clinical Trials For The World Of Crowdsourcing

Laurie Halloran | Xconomy | April 16, 2013

Disruption isn’t a word normally associated with clinical drug development, but nevertheless it is coming. [...] There are signals that drug development is starting to catch up with the general trend toward open collaboration and innovation. This trend is enabling tremendous advances in other industries, so why not ours? Read More »